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Abstract  
Male breast cancer (MBC) is an uncommon malignancy. We have previously reported that 
the expression of the Hippo transducers TAZ/YAP and their target CTGF was associated 
with inferior survival in MBC patients. Preclinical evidence demonstrated that Axl is a 
transcriptional target of TAZ/YAP. Thus, we herein assessed AXL expression to further 
investigate the significance of active TAZ/YAP-driven transcription in MBC. For this study, 
255 MBC samples represented in tissue microarrays were screened for AXL expression, and 
116 patients were included. The association between categorical variables was verified by the 
Pearson’s Chi-squared test of independence (2-tailed) or the Fisher Exact test. The 
relationship between continuous variables was tested with the Pearson's correlation 
coefficient. The Kaplan-Meier method was used for estimating survival curves, which were 
compared by log-rank test. Factors potentially impacting 10-year and overall survival were 
verified in Cox proportional regression models. AXL was positively associated with the 
TAZ/CTGF and YAP/CTGF phenotypes (p=0.001 and p=0.002, respectively). Patients with 
TAZ/CTGF/AXL- or YAP/CTGF/AXL-expressing tumors had inferior survival compared 
with non-triple-positive patients (log rank p=0.042 and p=0.048, respectively). The variables  
TAZ/CTGF/AXL and YAP/CTGF/AXL were adverse factors for 10-year survival in the 
multivariate Cox models (HR 2.31, 95%CI:1.02-5.22, p=0.045, and HR 2.27, 95%CI:1.00-
5.13, p=0.050). Nearly comparable results were obtained from multivariate analyses of 
overall survival. The expression pattern of AXL corroborates the idea of the detrimental role 
of TAZ/YAP activation in MBC. Overall, Hippo-linked biomarkers deserve increased 
attention in this rare disease. This article is protected by copyright. All rights reserved 
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INTRODUCTION  
Male breast cancer (MBC) is a rare disease often arising in elderly men (Ruddy and Winer, 
2013). Despite some recent molecular characterization efforts, its biology remains 
understudied (Piscuoglio, 2016; Johansson 2013; Kornegoor, 2012; Johansson, 2011; Callari, 
2011; Johansson, 2012; Fassan, 2009). Indeed, apart from hormone receptors that are 
frequently expressed (Anderson 2010; Shaaban, 2012), and whose targeting represents the 
mainstay of medical treatment (Doyen, 2010; Eggemann, 2013; Zagouri, 2013a; Zagouri, 
2013b; Di Lauro, 2013; Di Lauro, 2014; Di Lauro, 2015), little is known about the nature of 
deregulated molecular networks underlying the disease. Coherent with the paucity of data 
available so far, both in terms of biological processes and therapeutic targets, the European 
Organization for Research and Treatment (EORTC) has launched an initiative dedicated 
toward obtaining a better understanding of the disease (EORTC 10085, available at: 
http://www.eortc.org/research-groups/breast-cancer-group/ongoing-and-future-projects/).    
Over the past years, an Italy-UK collaboration was set off with the aim of investigating 
specific oncogenic pathways in MBC, and their relationship with clinical-pathological 
features and survival outcomes. On the basis of our preclinical experience, the focus was 
placed on signals connected with cancer stem cells (CSCs), a rare cellular subset whose 
hallmarks include self-renewal, ability to propagate the tumor in animal models, and 
resistance to current anticancer therapies (Beck and Blanpain, 2013). The evolutionary 
conserved Hippo signaling pathway was chosen for proof-of-principle studies, considering 
that both our group and others demonstrated that TAZ/YAP-mediated gene transcription is 
associated with the retention/acquisition of stem-like features, self-renewal, epithelial-
mesenchymal transition, chemoresistance and metastatic dissemination in breast CSC 
(BCSC) models (Bartucci, 2015; Cordenonsi, 2011; Xiang, 2014; Chang, 2015; Nandy, 
2015). Moreover, our proof-of-concept clinical studies connected the expression of 
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TAZ/YAP to inferior therapeutic and survival outcomes in female breast cancer patients who 
received neoadjuvant therapy (Vici, 2014; Vici, 2016). 
Hippo is a “two face” pathway, composed by two modules that, in a neoplastic background, 
elicit opposite biological outcomes (Johnson and Halder, 2014). While core kinases (MST1/2 
and LATS1/2) and adaptors (SAV1 and MOB1A/1B) act as tumor suppressors by mediating 
nuclear exclusion, cytoplasmic retention and proteasomal degradation of the Hippo 
transducers TAZ/YAP, these, together with their DNA binding platform chiefly consisting in 
TEAD factors, have been extensively connected with tumor-promoting functions (Johnson 
and Halder, 2014). Many tumors exhibit defective activation of core Hippo kinases/adaptors, 
and/or  activation of upstream or lateral signals that, albeit not canonically placed within the 
pathway architecture, can directly activate TAZ/YAP (Piccolo, 2014).   
In MBC, we have previously reported that the expression of TAZ/YAP and their established 
target CTGF conferred inferior survival outcomes (Di Benedetto, 2016a). To provide further 
insights into the oncogenic role of TAZ/YAP in such an uncommon tumor, we herein 
assessed AXL, a member of the TAM family of receptor tyrosine kinases (RTKs) (Graham, 
2014), as the Axl gene is a direct target of the Hippo transcriptional machinery (Azzolin, 
2014; Zanconato, 2015). In turn, compelling evidence demonstrated that AXL mediates a 
variety of oncogenic functions, spanning from cancer cell survival to therapeutic resistance 
(Graham, 2014), and AXL expression has been reported in a number of hematological and 
epithelial malignancies (Wu, 2014). Overall, the present study was designed with the goals of 
i) describing the expression pattern of AXL, and ii) providing further ground on the clinical 
potential of Hippo-related biomarkers in MBC. 
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MATERIALS AND METHODS 
Study Participants and procedures 
For this retrospective analysis samples from 255 histologically confirmed, non-metastatic 
MBC patients, represented in tissue microarrays (TMAs) (Shaaban, 2012), were 
immunostained for evaluating the expression of AXL. Eligibility was assessed based on the 
following criteria: i) complete data on AXL, ii) complete data on TAZ, YAP and CTGF, iii) 
complete data on the following routine clinical-pathological features: histology, tumor grade, 
hormone receptors (ER, PgR) and Ki-67, and iv) availability of survival data. On this basis, 
116 patients were included. Nodal status was not considered among the inclusion criteria, 
given that this information was available for 87 patients only. As already specified, tamoxifen 
was the most commonly administered agent in the adjuvant setting, albeit complete 
information pertinent to post-surgical therapy were not available (Shaaban, 2012). This study 
was conducted in accordance with the Declaration of Helsinki and approved by the 
Institutional Review Board of the “Regina Elena” National Cancer Institute of Rome and by 
the Leeds (East) Research Ethics Committee (06/Q1205/156). Samples were anonymised to 
the research team and informed consent was not required (Shaaban, 2012). This study 
adheres to the REMARKS guidelines (McShane; 2006). 
 Immunohistochemistry 
TMAs were built from formalin-fixed paraffin-embedded (FFPE) material (Shaaban, 2012). 
The immunohistochemical assessment of AXL was performed using the polyclonal antibody 
anti-AXL (HPA037422, Sigma-Aldrich, St. Louis, USA) at the dilution of 1:200. AXL 
expression was determined both in terms of staining intensity on a four-grade scale (0: 
negative, 1+: weak, 2+: moderate, 3+: strong) and percentage of tumor-expressing cells (0-
100%). Samples were considered positive if ≥30% of neoplastic cells exhibited a distinct 
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membranous/cytoplasmic immunoreactivity of any intensity. This cutoff reflected the lowest 
percentage of AXL-expressing cells observed in this cohort (range 30-90%). Two 
investigators (ADB and MM) evaluated immunoreactivity. The modalities used for assessing 
TAZ, YAP, CTGF, hormone receptors and Ki-67 levels were detailed elsewhere (Shaaban, 
2012; Di Benedetto, 2016a). 
Statistical analysis 
The relationship between categorical variables was assessed with the Pearson’s Chi-squared 
test of independence (2-tailed) or the Fisher Exact test. The Pearson's correlation coefficient 
was used to establish the correlation between continuous variables. Survival curves were 
estimated and compared with the Kaplan-Meier method and log-rank test, respectively. 
Overall survival (OS) was calculated as the time from diagnosis to death due to any cause. 
For 10-year survival analysis, patients who experienced the outcome of interest after this time 
point were censored. Potential predictors of 10-year and overall survival were verified in uni- 
and multivariate Cox proportional regression models. The final multivariate models were 
built by adjusting for standard clinical-molecular variables (invasive ductal carcinoma 
(IDC)/invasive lobular carcinoma (ILC) vs other histotypes, G3 vs G1-2, ER+/PgR+ vs other, 
Ki-67 high vs Ki-67 low) independently on whether these factors were significant at the 
univariate assessment. Statistical significance was set at p<0.05. Statistical analyses were 
carried out using SPSS software (SPSS version 21, SPSS Inc., Chicago, IL, USA).   
RESULTS  
Association between AXL expression and clinical-pathological factors 
For this study, 255 MBC samples were screened for the expression of AXL and, based on the 
aforementioned eligibility criteria, 116 patients were included in the final analysis. 
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Representative immunohistochemical staining is presented in Figure 1.  Baseline 
characteristics of the patients who met the eligibility criteria are summarized in Table 1. As 
shown in Table 2, we did not observe any significant association between AXL and standard 
clinical-pathological factors, namely histology, nodal status, tumor grade, hormone receptor 
status, Ki-67. Conversely, AXL was positively associated with the TAZ/CTGF and 
YAP/CTGF phenotypes (chi2 p=0.001 and p=0.002, respectively, as reported in Table 2). 
Moreover, a significant positive correlation, in terms of percentage of tumor-expressing cells, 
was seen between AXL and CTGF (Pearson's correlation coefficient=0.285; p=0.002, data 
available upon request).  Overall, these data support our hypothesis of active TAZ/YAP-
driven gene transcription in a subset of MBC patients.  
 
Relationship between the TAZ/CTGF/AXL and  YAP/CTGF/AXL phenotypes and 
clinical outcomes  
Patients whose tumors had a triple-positive phenotype (TAZ/CTGF/AXL or 
YAP/CTGF/AXL) experienced shorter survival compared with their negative counterparts 
(log rank p=0.042 and p=0.048, respectively. Figure 2, panel A and B), analogously to the 
TAZ/CTGF and YAP/CTGF models that we previously connected with inferior survival 
outcomes. Results from the univariate regression analyses, presented in Table 3, performed 
for identifying variables impacting 10-year survival confirmed that the TAZ/CTGF/AXL and 
YAP/CTGF/AXL phenotypes  are adverse prognostic indicators (HR 2.37, 95%CI: 1.05-5.34, 
p=0.038, and HR 2.31, 95%CI:1.02-5.22, p=0.044, respectively). The multivariate Cox 
models (Table 3) confirmed these data (TAZ/CTGF/AXL: HR 2.31, 95%CI: 1.02-5.22, 
p=0.045. YAP/CTGF/AXL: HR 2.27, 95%CI:1.00-5.13, p=0.050). Nearly comparable 
results, even though with a trend toward statistical significance, were obtained in the 
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multivariate Cox models for overall survival (TAZ/CTGF/AXL: HR 2.19, 95%CI: 0.97-4.94, 
p=0.058. YAP/CTGF/AXL: HR 2.16, 95%CI:0.96-4.87, p=0.063) (Table 4).  
 
DISCUSSION 
The present study aimed at providing further evidence supporting the negative prognostic 
significance of active TAZ/YAP-mediated gene transcription in MBC patients. To this end, 
116 MBC samples, previously characterized for the expression of TAZ, YAP and CTGF (Di 
Benedetto, 2016a), were immunostained for AXL, another established target of the Hippo 
transducers. The message conveyed by the present study is that: i) AXL expression is 
significantly associated with the TAZ/CTGF and YAP/CTGF phenotypes, and positively 
correlated with CTGF, an established TAZ/YAP target gene, ii) patients whose tumors 
harbored the TAZ/CTGF/AXL and YAP/CTGF/AXL molecular backgrounds had adverse 
survival outcomes compared with patients whose tumors did not show molecular evidence of 
TAZ/YAP activation, and iii) the prognostic significance of the triple-positive model herein 
investigated was comparable to that of the previously described TAZ/CTGF and YAP/CTGF 
models, further enforcing the hypothesis that deregulation of the Hippo machinery may 
represent an important source of oncogenic stimuli in MBC.  
We acknowledge that, being retrospective in nature, our study has some limitations, chiefly 
the fact that we were unable to consider cancer-specific events owing to the lack of complete 
information related to the cause of death, as discussed elsewhere (Di Benedetto, 2016a). 
Nevertheless, ten-year survival is a suitable endpoint to overcome this drawback, when 
considering that MBC is a disease of elderly men and with a long natural history, comparable 
to that of luminal-type breast cancer arising in post-menopausal women (Ruddy and Winer, 
2013).  Overall, our analyses at an intermediate time point (10-year survival) conveyed the 
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message that deregulated Hippo pathway is involved in the genesis of MBC, analogously to 
earlier preclinical and clinical reports in female breast cancer (Maugeri-Saccà, 2015).  
 
Next, our interest towards the Hippo pathway in MBC extends beyond the analysis of key 
pathway components. Indeed, we are currently analyzing other pathways intersecting the 
Hippo cascade at various levels. Bearing in mind the number of molecular signals interacting 
with the Hippo cascade (Piccolo, 2014), we focused our attention on the following: i) the 
mevalonate pathway and, ii) the DNA damage repair (DDR) machinery. Evidence of 
metabolic control of the Hippo pathway stemmed from a high-throughput screening of Food 
and Drug Administration (FDA)-approved compounds performed in the attempt of 
identifying TAZ/YAP modulators through a drug repositioning approach. This screening 
identified both hydrophilic and lipophilic statins,  a class of widely prescribed cholesterol-
lowering medications, as the most potent TAZ/YAP modulators. Mechanistically, it was 
demonstrated that the mevalonate pathway promotes TAZ/YAP activation via the production 
of geranylgeranyl pyrophosphate (GGPP), which is essential for correct membrane 
localization, and consequently activation, of Rho GTPases (Sorrentino, 2014). These, in turn, 
inhibit TAZ/YAP phosphorylation independently on the activity of core Hippo pathway 
kinases (LATS1/2). Interestingly, the effects of statins were reproduced with the 
administration of nitrogen-containing bisphosphonates, such as zoledronic acid, a class of 
compounds that inhibit farnesyl pyrophosphate synthase, another key enzyme in the 
mevalonate cascade (Sorrentino, 2014). Overall, the preclinically documented metabolic 
control of TAZ/YAP operated by the mevalonate pathway, together with the association 
between obesity and MBC, makes the mevalonate pathway an attractive therapeutic target in 
MBC (Humphries, 2015). Our results  indicates that 3-Hydroxy-3-methylglutharylcoenzyme 
A reductase (HMG-CoAR), the rate-limiting enzyme of the mevalonate cascade and the 
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target of statins (Buhaescu and Izzedine, 2007), is significantly co-expressed with Hippo 
transducers, suggesting that the mevalonate pathway regulates the activity of TAZ/YAP (Di 
Benedetto, 2016b). When reanalyzing this association in light of the data on AXL herein 
presented, we confirmed that HMG-CoAR is positively associated with both the 
TAZ/CTGF/AXL and YAP/CTGF/AXL phenotypes (Fisher Exact test p=0.024 and p=0.014, 
respectively). Regarding the DDR, a wave of preclinical evidence connected key 
orchestrators of the DDR network, namely ATM and ATR, with the Hippo pathway (Pefani 
DE and O'Neill, 2016). In a greater detail, Hippo pathway kinases are targeted by the 
ATM/Chk2 and ATR/Chk1 pathways, thus participating in an array of interconnected 
biological processes spanning from cell-cycle checkpoint activation and replication fork 
stability to DNA repair and apoptosis (Pefani DE and O'Neill, 2016). The molecular 
cooperation between the Hippo pathway and the molecular network safeguarding genome 
integrity is further enforced when considering the interactions between Hippo pathway 
components and p53. Indeed, it was demonstrated that LATS2 stabilizes p53 (Ganem NJ, 
2014), and that LATS1/2 silencing shifted p53 function toward an oncogenic (gain-of-
function), mutant-like state (Furth N, 2015). Moreover, YAP physically interacts with mutant 
p53 proteins promoting the aberrant expression of cell cycle‐related genes (Di Agostino S, 
2016). Our group initiated characterization of the ATM-Chk2 and ATR-Chk1 axes in MBC, 
with the aim of providing novel information on DNA repair-linked biomarkers and their 
connection with the Hippo machinery and metabolic avenues.  
We believe that our efforts toward achieving a better comprehension of the molecular basis of 
MBC potentially hold important therapeutic implications. Indeed, inhibition of the Hippo 
transducers TAZ/YAP was preclinically obtained with various Food and Drug 
Administration- (FDA) approved compounds, such as statins, bisphosphonates, verteporfin, 
dobutamine, metformin, and dasatinib (Sorrentino, 2014; Frangou, 2014; Rosenbluh, 2012; 
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Liu-Chittenden, 2012; Yu, 2014;  Bao, 2011; Wang, 2014; DeRan, 2014 ). In our opinion, 
agents targeting the mevalonate pathway (e.g. statins and nitrogen-containing 
bisphosphonates) and glucose-lowering compounds (e.g. metformin) are those for which it is 
plausible gathering retrospective, hypothesis-generating data. Indeed, a non-negligible 
fraction of MBC patients supposedly received these treatments for co-existing medical 
conditions, such as elevated cholesterol levels, osteoporosis and diabetes, since these 
comorbidities are fairly common in elderly men. Reconsidering survival outcomes of MBC 
patients in light of the use of these agents, target expression, and activation of the TAZ/YAP-
mediated oncogenic program is a strategy to be pursued.   
In summary, by analyzing AXL, an established target of TAZ/YAP widely exploited in the 
preclinical setting as a proxy of their activation, we herein provided further evidence to the 
detrimental role of activated Hippo transducers in MBC. Furthermore, ongoing investigations 
will shortly help elucidate the connection between Hippo and other oncogenic signals. 
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Figure Legends 
Figure 1: Representative examples of immunohistochemical expression of AXL, TAZ, YAP 
and CTGF in MBC samples. Panels a-b-c show a sample with cytoplasmic AXL expression 
(a) cytoplasmic/nuclear TAZ (b) and cytoplasmic CTGF (c). In panels d-f, a tumor case with 
cytoplasmic AXL expression (d), cytoplasmic/nuclear YAP (e) and cytoplasmic CTGF (f). 
Scale bar 30 μm.  Magnification 40x. Inset magnification 10x.  
Figure 2: Kaplan-Meier survival curves of overall survival regarding: (A) TAZ/CTGF/AXL 
and (B) YAP/CTGF/AXL (N=116). 
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Table 1: Baseline characteristics of MBC patients characterized for the expression of AXL 
(N=116) 
  
Abbreviations: ER: estrogen receptor, IDC: invasive ductal carcinoma, ILC: invasive lobular 
carcinoma, PgR: progesterone receptor. 
* ER+/PgR-  (N=15), ER-/PgR- (N=2) 
Characteristics 
 
 N (%) 
 
Age at diagnosis Median (min-max) [IQ 
range] 
67 (34-88) [59-75] 
 
Histology IDC/ILC  101 (87.1) 
 Other  15 (12.9) 
 
Grade G1-2 57 (49.1) 
 G3 59 (50.9) 
 
Nodal status Positive 50 (43.1) 
 Negative 37 (31.9) 
 Unknown  29 (25.0) 
 
Hormone Receptors Positive (ER+/PgR+) 99 (85.3) 
 Other* 17 (14.7) 
 
Ki-67 High (≥14%) 51 (44.0) 
 Low (<14%) 65 (56.0) 
 
TAZ/CTGF Positive 43 (37.1) 
 Negative 73 (62.9) 
 
YAP/CTGF Positive 48 (41.4) 
 Negative 68 (58.6) 
 
AXL Positive 37 (31.9) 
 Negative 79 (68.1) 
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Table 2: Association between AXL, clinical-pathological factors and expression of the 
TAZ/CTGF and YAP/CTGF phenotypes.   
 
 
 
Abbreviations: ER: estrogen receptor, IDC: invasive ductal carcinoma, ILC: invasive lobular 
carcinoma, PgR: progesterone receptor. 
* Fisher's Exact Test 
 
 
 
  AXL Chi2 Test 
  Positive Negative p-value 
  N(%) N(%)  
Histology IDC/ILC  32 (31.7) 69 (68.3)  0.999* 
 Other 5 (33.3) 10 (66.7) 
 
 
Grade G1-2 14 (24.6) 43 (75.4) 0.096 
 G3 23 (39.0) 36 (61.0) 
 
 
Nodal status Positive 18 (36.0) 32 (64.0) 0.666 
 Negative 15 (40.5) 22 (59.5) 
 
 
Hormone Receptors ER+/PgR+ 31 (31.3) 68 (68.7) 0.745 
 Other 6 (35.3) 11 (64.7) 
 
 
Ki-67 High 17 (33.3) 34 (66.7) 0.769 
 Low 20 (30.8) 45 (69.2) 
 
 
TAZ/CTGF Positive 22 (51.2) 21 (48.8) 0.001 
 Negative 15 (20.5) 58 (79.5) 
 
 
YAP/CTGF Positive 23 (47.9) 25 (52.1) 0.002 
 Negative 14 (20.6) 54 (79.4)  
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Table 3: Uni- and multivariate Cox regression models  for 10-year survival  ( N=116) 
 
  Univariate Cox  
regression 
model 
Multivariate 
Cox 
regression 
model 
Multivariate 
Cox 
regression 
model 
  HR 
(95%CI
) 
p-
valu
e 
HR 
(95%CI
) 
p-
valu
e 
HR 
(95%CI
) 
p-
valu
e 
Histology IDC/ILC vs 
other 
1.20 
(0.36-
3.96) 
0.762 
1.00 
(0.30-
3.34) 
0.99
4 
1.02 
(0.30-
3.42) 
0.97
7 
Grade G3 vs G1-2 1.84 
(0.89-
3.80) 
0.099 
1.69 
(0.79-
3.60) 
0.17
5 
1.70 
(0.80-
3.63) 
0.16
9 
Hormone 
Receptors 
ER+/PgR+ vs 
other 
      0.66 
(0.28-1.54  
0.335 
0.71 
(0.29-
1.71) 
0.44
7 
0.71 
(0.29-
1.71) 
0.44
8 
Ki-67 High vs Low 1.18 
(0.58-
2.39) 
0.655 
1.13 
(0.54-
2.38) 
0.73
7 
1.13 
(0.54-
2.36) 
0.75
3 
TAZ/CTGF/AX
L 
TAZ/CTGF/AX
L vs other 
      2.37 
(1.05-5.34  
0.038 
2.31 
(1.02-
5.22) 
0.04
5 
  
YAP/CTGF/AX
L 
YAP/CTGF/AX
L vs other 
      2.31 
(1.02-5.22  
0.044   
2.27 
(1.00-
5.13) 
0.05
0 
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Table 4: Univariate and multivariate Cox regression models for overall survival  (N=116).  
 
  Univariate Cox  
regression 
model 
Multivariate 
Cox 
regression 
model 
Multivariate 
Cox 
regression 
model 
  HR 
(95%CI
) 
p-
valu
e 
HR 
(95%CI
) 
p-
valu
e 
HR 
(95%CI
) 
p-
valu
e 
Histology IDC/ILC vs 
other 
1.30 
(0.40-
4.29) 
0.662 
1.11 
(0.33-
3.70) 
0.87
1 
1.13 
(0.34-
3.77) 
0.84
8 
Grade G3 vs G1-2 1.94 
(0.94-
3.97) 
0.071 
1.85 
(0.88-
3.91) 
0.10
6 
1.86 
(0.88-
3.93) 
0.10
3 
Hormone 
Receptors 
ER+/PgR+ vs 
other 
     0.76 
(0.32-1.76  
0.519 
0.85 
(0.35-
2.04) 
0.71
8 
0.85 
(0.35-
2.04) 
0.71
9 
Ki-67 High vs Low 1.09 
(0.54-
2.18) 
0.805 
1.01 
(0.49-
2.08) 
0.98
2 
1.00 
(0.48-
2.07) 
0.99
5 
TAZ/CTGF/AX
L 
TAZ/CTGF/AX
L vs other 
      2.26 
(1.01-5.08  
0.048 
2.19 
(0.97-
4.94) 
0.05
8 
  
YAP/CTGF/AX
L 
YAP/CTGF/AX
L vs other 
      2.21 
(0.98-4.97  
0.054   
2.16 
(0.96-
4.87) 
0.06
3 
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